Hypercalcemia with nephrocalcinosis and impaired renal function due to increased Parathyroid hormone secretion at onset of childhood acute lymphoblastic leukemia.

Leuk Lymphoma

Department of Pediatric Hematology, Oncology, and Immunology, Center of Pediatric and Adolescent Medicine, University Hospital Düsseldorf, Düsseldorf, Germany.

Published: August 2004

The present case report contributes new aspects to the etiology and the appearance of hypercalcemia at the onset of childhood acute lymphoblastic leukemia [ALL]. Malignancy associated hypercalcemia is often associated with an increase of Parathyroid hormone-related protein [PTHrP]. In our case PTHrP was normal but high levels of Parathormon [PTH] were measured. This increase of PTH was not due to hyperparathyroidism nor was it due to osteolytic lesions or metabolic disease interfering with bone density. The most likely explanation for high PTH levels in our case was that PTH was secreted by leukemic blasts and thus responsible for hypercalcemia. Uncommonly, hypercalcemia was clinically associated with moderate renal impairment and marked nephrocalcinosis.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190410001683804DOI Listing

Publication Analysis

Top Keywords

onset childhood
8
childhood acute
8
acute lymphoblastic
8
lymphoblastic leukemia
8
hypercalcemia
5
hypercalcemia nephrocalcinosis
4
nephrocalcinosis impaired
4
impaired renal
4
renal function
4
function increased
4

Similar Publications

Introduction: Systemic lupus erythematosus (SLE) causes widespread inflammation and damage in affected organs. Severity is determined by the type of organ systems affected and the extent of involvement. SLE occurs in childhood or adulthood and disease severity varies according to age of onset.

View Article and Find Full Text PDF

Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.

View Article and Find Full Text PDF

Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased risk of early mortality. High doses of sodium channel blockers are typically used to treat SCN8A-DEE caused by gain-of-function (GoF) variants. However, seizures are often drug resistant, and only a few patients achieve seizure freedom.

View Article and Find Full Text PDF

Dyke-Davidoff-Masson syndrome (DDMS) is a rare neurological disorder characterized by cerebral hemiatrophy, leading to seizures, hemiparesis, and cognitive deficits. We report the case of a 20-year-old female with a history of chronic seizure disorder and left-sided hemiparesis. The patient experienced her first seizure at 6 months of age, followed by recurrent generalized tonic seizures throughout childhood.

View Article and Find Full Text PDF

Antipsychotic treatment is associated with cardiometabolic risks that may be especially detrimental to children and adolescents. In this Danish population-based cohort study, we included individuals with psychiatric diagnoses who initiated antipsychotics in 2000-2021 at age 6-31 years. We assessed the risk of cardiometabolic adverse events up to 10 years following incident exposure to antipsychotics, compared to age- and sex-matched unexposed individuals with psychiatric diagnoses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!